WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader focused on improving the health and safety of people and the environment, today announced that it has acquired chemagen Biopolymer-Technologie AG, a key player in the field of automated nucleic acid isolation, as part of the Company’s strategy to advance its offerings to the molecular diagnostics and research markets.
Daniel R. Marshak, PhD, chief scientific officer and president, Emerging Diagnostics, PerkinElmer, said, “The addition of chemagen's complementary products to PerkinElmer’s portfolio will provide the Company with robust platforms and solutions to meet the needs of the rapidly evolving molecular diagnostics market. The hardware and reagent capabilities brought by chemagen include a total solution in nucleic acid sample preparation, with automation-enabling features that can power high throughput applications in research, screening, and diagnostics.”
He added, “Nucleic acids are the building blocks of DNA and RNA, modulators of genetic function and information. Our ability to provide automated nucleic acid isolation technologies through this acquisition significantly facilitates applications such as large-scale pathogen detection in blood banking, human genetics applications such as HLA typing, autoimmune analysis and tissue rejection analysis. PerkinElmer has worked with chemagen for years to provide automated liquid-handling platforms with DNA preparation capabilities. chemagen is a natural fit with our business.”
chemagen AG, based in Baesweiler, Germany was founded in December 1997. The company's scientific foundations were laid at the RWTH Technical University of Aachen. In July 2009, chemagen founded a United States subsidiary.
Factors Affecting Future Performance
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products decline or do not grow as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or to successfully divest businesses; (5) our failure to adequately protect our intellectual property; (6) the loss of any of our licenses or licensed rights; (7) our ability to compete effectively; (8) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (9) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (10) disruptions in the supply of raw materials and supplies; (11) the manufacture and sale of products may expose us to product liability claims; (12) our failure to maintain compliance with applicable government regulations; (13) regulatory changes; (14) our failure to comply with healthcare industry regulations; (15) economic, political and other risks associated with foreign operations; (16) our ability to retain key personnel; (17) significant disruption in our information technology systems; (18) restrictions in our credit agreements; (19) our ability to realize the full value of our intangible assets; (20) significant fluctuations in our stock price; (21) reduction or elimination of dividends on our common stock; and (22) other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
About chemagen AG
chemagen is a key player in the field of automated nucleic acid isolation. The purification of DNA, RNA, or viral DNA/RNA is facilitated through chemagen’s proprietary M-PVA Magnetic Bead technology. chemagen’s high performance instrument is the chemagic MSM I. It enables the automated separation of nucleic acids from sample volumes between 10 μl 10 ml. Kits are available for isolation and purification of nucleic acids from blood, serum/plasma, tissue, saliva, buccal swabs, amniotic fluid and feces. With the chemagic Prepito, chemagen offers a benchtop walk-away instrument relying upon the proven separation technology for up to 1000 µl sample material and 1 – 12 samples in parallel.
Outstanding robustness, minimal hands-on time and fast automated applications translate to the highest throughput and flexibility of laboratory workflows.
Find further information on www.chemagen.com
About PerkinElmer, Inc.
PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $1.7 billion in 2010, has about 6,200 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.